Ursolic Acid Exhibits Potent Anticancer Effects in Human Metastatic Melanoma Cancer Cells (SK-MEL-24) via Apoptosis Induction, Inhibition of Cell Migration and Invasion, Cell Cycle Arrest, and Inhibition of Mitogen-Activated Protein Kinase (MAPK)/ERK Signaling Pathway

Background: Ursolic acid is an important bioactive triterpenoid that has been reported to be of tremendous pharmacological importance. However, the anticancer potential of ursolic acid has not been examined against metastatic melanoma cells. Therefore, in this study we examined the anticancer potential of ursolic acid and its mode of action.

Material/Methods: WST-1 and colony formation assays were used for cell viability assessment. Cell cycle analysis was performed by flow cytometry. Apoptosis was detected by AO/EB staining using fluorescence microscopy. Cell migration and invasion were assessed by Boyden chamber assay. Protein expression was checked by Western blotting.

Results: The results revealed that ursolic acid exerts significant (p<0.01) growth-inhibitory effects on SK-MEL-24 cells. The IC$_{50}$ of ursolic acid against SK-MEL-24 cells was 25 µM. Our investigation of the underlying mechanism revealed that ursolic acid prompts apoptotic cell death of the SK-MEL-24 cells, which was linked with increased expression of Bax and Caspase 3 and 9, and decreased expression of Bcl-2. Ursolic acid also halted the SK-MEL-24 cells at G0/G1 phase of the cell cycle and also downregulated the expression of Cyclin B1 and Cdc25. Ursolic acid significantly (p<0.01) inhibited the migration and invasion of SK-MEL-2 cells, indicative of its antimetastatic potential. Finally, ursolic acid inhibited the MAPK/ERK pathway by suppressing the expression of p-P38 and p-ERK.

Conclusions: Ursolic acid appears to be a potent molecule for the treatment of melanoma.

MeSH Keywords: Apoptosis • Apoptosis Inducing Factor • Cell Cycle • Flow Cytometry • gp100 Melanoma Antigen

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/913069
Background

Nature has bestowed mankind with a structurally diverse chemical compounds for alleviating human ailments [1]. With recent progress in science, more and more natural products are being screened for their medicinal properties [2]. Among these natural products, plants and microbes have been the major sources of drugs [3]. A number of today’s drugs come from plants. For example, an anti-malarial drug, artemisinin, has saved millions of lives [4]. Similarly, many anticancer drugs are of plant origin [5]. Although plants produce these metabolites for their own needs, humans have utilized them for their own benefit for thousands of years [6]. The plant secondary metabolites have been categorized into different group based on their structural properties. Triterpenoids constitute a vast group of plant metabolites [7]. Triterpenes have been shown to exhibit remarkable anticancer effects and are believed to be prospective anticancer agents [7]. Ursolic acid is a triterpenoid that has been evaluated against different types of cancer cells [8]. For example, ursolic acid inhibits the proliferation of the lung cancer cells [9]. However, the anticancer properties of ursolic acid are yet to be investigated against metastatic melanoma cells. Melanoma accounts for approximately 4% of cancer-related deaths and it is the sixth most common type of cancer in the United States. It has been reported that 1 in every 5 individuals develops skin cancer in the United States [10]. There is solid evidence that exposure to ultraviolet radiation initiates the development of melanoma, and much research attention has been focused on the potential of natural products to protect against UVR-induced skin cancer [11]. In the present study we assessed the anticancer effects of a plant triterpenoid, ursolic acid, against metastatic SK-MEL-24 melanoma cells, showing that ursolic acid inhibits the growth of SK-MEL-24 cells in a concentration-dependent manner. These anticancer effects of ursolic acid were found to be due to triggering of apoptosis. Ursolic acid also blocked the cell division of the cancer cells by arresting the cells in the G1/G0 phase of the cell cycle. The anti-metastatic potential of ursolic acid was examined by cell migration and invasion assays and we found that ursolic acid inhibited migration and invasion of SK-MEL-24 cells by targeting the MAPK/ERK signaling pathway. Our results show that ursolic acid may prove beneficial in the management of metastatic melanoma.

Material and Methods

Cell culture conditions

SM-MEL-24 human metastatic melanoma cancer cells were obtained from the Cancer Research Institute of Beijing (Beijing, China) and maintained in Dulbecco’s modified Eagle’s medium (Invitrogen Life Technologies, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, MA, USA), 100 µg/ml streptomycin, and 100 U/ml penicillin G (Himedia, PA, USA) in an incubator at 37°C with 5% CO2.

WST-1 cell viability and colony-formation assay

The anticancer effect of ursolic acid was assessed on metastatic melanoma cells by WST-1 assay. In brief, the SK-MEL-24 cancer cells were cultured at a density of 2.5×10⁴ cells/well in 96-well plates and subjected to treatment with varied concentrations of ursolic acid (0–200 µM). This was followed by incubation of SK-MEL-24 cells with WST-1 for 3 h at 37°C, and the proliferation rate was determined by measuring absorbance at 450 nm. The morphology of ursolic acid-treated cells was also examined by phase-contrast microscopy. The effect of ursolic acid on the formation of SK-MEL-24 colonies was investigated as described earlier [12].

Acridine orange and Ethidium bromide (AO/EB) staining for apoptosis

For AO/EB staining, the melanoma SK-MEL-24 cells (0.6×10⁴) were grown in 6-well plates. Following incubation for 12 h, the SK-MEL-24 cells were subjected to ursolic acid treatment (0, 12.5, 25, and 50 µM) for 24 h at 37°C. As the cells sloughed off, 25-µl cell cultures were put onto glass slides and subjected to staining with a solution (1 µl) of AO and EB. The slides were covered with a coverslip and examined with a fluorescence microscope.

Cell cycle analysis

The distribution of the metastatic melanoma SK-MEL-24 cells in different cell cycle phases was performed by flow cytometry after PI staining using a method reported previously [13]. In brief, the SK-MEL-24 cells were grown in 6-well plates and treated with ursolic acid (0, 12.5, 25, and 50 µM) for 24 h at 37°C. The cells were then collected and washed with PBS, followed by fixation in ethanol (70%). After overnight incubation at 4°C, the cells were subjected to PI staining and subjected to flow cytometry.

Cell migration and invasion assays

For cell migration and invasion analysis, the metastatic melanoma SK-MEL-24 cells were subjected to treatment with 0, 12.5, 25, and 50 µM concentrations of ursolic acid. The cell migration and invasion assays were then performed as described previously [14].

Western blotting

After the lysis of the SK-Mel-24 cancer cells in RIPA lysis buffer, the protein content of each lysate was estimated by BCA assay.
The samples were then loaded on the SDS-PAGE. The gels were then transferred to nitrocellulose membranes and subjected to treatment with primary antibody at 4°C for 24 h. After this, the membranes were incubated with HRP-conjugated secondary antibody (1:1000) for 50 min at 25°C. Enhanced chemi-luminescence reagent was used to visualise the protein bands.

**Statistical analysis**

The experiments were performed 3 times and the values are presented as the mean ± standard deviation of the 3 replicates. We used the t test (for comparison between 2 samples) and one-way ANOVA followed by Tukey’s test (for comparison between more than 2 samples) for statistical analysis using GraphPad Prism software (version 7; GraphPad Software, Inc., La Jolla, CA, USA). P<0.01 was considered a statistically significant difference.
Results

**Ursolic acid exerts antiproliferative effects on SK-MEL-24 melanoma cells**

The effects of ursolic acid (Figure 1A) on the metastatic SK-MEL-24 melanoma cells was examined by WST-1 assay. We found that ursolic acid exerts antiproliferative effects on the SK-MEL-24 melanoma cell line and had an IC\textsubscript{50} of 25 µM (Figure 1B). In addition, we found that the anticancer effects of ursolic acid on melanoma cells exhibited a dose-dependent pattern. The investigation of the ursolic acid-treated SK-MEL-24 cells revealed that ursolic acid significantly inhibited the colony formation ability of SK-MEL-2 cells (Figure 2).

**Ursolic acid triggers apoptosis in SK-MEL-24 melanoma cells**

Ursolic acid triggered apoptotic cell death of metastatic melanoma SK-MEL-24 cells after the cells were treated with ursolic acid and subjected to AO/EB staining. The results of AO/EB assay showed that ursolic acid induced apoptotic cell death in the SK-MEL-24 melanoma cells (Figure 3). Analysis of the protein expression of the apoptosis biomarker proteins revealed that ursolic acid increase in the expression of Bax and cleaved caspase 3 and 9, while the expression of Bcl-2 decreased in a concentration-dependent manner (Figure 4).

**Ursolic acid triggers G\textsubscript{0}/G\textsubscript{1} arrest of SK-MEL-24 melanoma cells**

The effects of ursolic acid on the distribution of SK-MEL-24 melanoma cells (SK-MEL-24) in various cell cycle phases was assessed by flow cytometry. We found that ursolic acid caused a remarkable increase in the percentage of SK-MEL-24 melanoma cells in G\textsubscript{0}/G\textsubscript{1} phase of the cell cycle. The percentage of...
SK-MEL-24 melanoma cells in G2 phase increased from 58.5% to 79.4% upon treatment with ursolic acid (Figure 5). These results clearly indicate that ursolic acid induces G0/G1 cell cycle arrest of SK-MEL-24 melanoma cells. Moreover, G0/G1 cell cycle arrest of SK-MEL-24 cells by ursolic acid was also associated with suppression of Cyclin B1 and Cdc2 expression in a concentration-dependent manner (Figure 6).

**Figure 5.** Effect of ursolic acid on cell cycle distribution of SK-Mel-24 cells. The results show that ursolic acid triggers G0/G1 cell cycle arrest in a concentration-dependent manner. The experiments were carried out 3 times.

SK-MEL-24 melanoma cells in G2 phase increased from 58.5% to 79.4% upon treatment with ursolic acid (Figure 5). These results clearly indicate that ursolic acid induces G0/G1 cell cycle arrest of SK-MEL-24 melanoma cells. Moreover, G0/G1 cell cycle arrest of SK-MEL-24 cells by ursolic acid was also associated with suppression of Cyclin B1 and Cdc2 expression in a concentration-dependent manner (Figure 6).

**Ursolic acid inhibits the migration and invasion of the SK-MEL-24 cells**

The anti-metastatic effects of ursolic acid were investigated by cell migration and invasion assays. We found that ursolic acid treatment inhibited the migration of the cancer cells in a dose-dependent fashion (Figure 7). Similar effects were also exhibited by ursolic acid on the invasion of SK-MEL-2 cells (Figure 8).

**Ursolic acid inhibits the MAPK/ERK signaling pathway**

Several of the signaling pathways are activated in cancer cells, and those pathways are considered important targets for anticancer drugs. The effect of ursolic acid was also investigated on the MAPK/ERK signaling pathway in SK-MEL-24 cells. We found that ursolic acid causes considerable decrease in the expression of the p-P38 and p-ERK proteins. However, no visible effect was observed on total P38 and ERK protein expression, and this effect was concentration-dependent (Figure 9).

**Discussion**

Melanoma is a deadly cancer accounting for approximately 4% of all cancer-related mortalities [10]. The lack of effective drug...
**Figure 6.** Effect of ursolic acid on the expression of cell cycle-related proteins in the SK-Mel-24 cells as shown by Western blotting. The experiments were performed 3 times.

**Figure 7.** Effect of ursolic acid on the migration of SK-Mel-24 cells as shown by Western blotting. The results show that ursolic acid inhibits cell migration in a concentration-dependent manner. The results are the means of 3 replicates ±SD (*p<0.01).

**Figure 8.** Effect of ursolic acid on the invasion of the SK-Mel-24 cells. The results show that ursolic acid inhibits cell invasion in a concentration-dependent manner. The results are the means of 3 replicates ±SD (*p<0.01).
found that ursolic acid causes the apoptosis of SK-MEL-24 cells in a dose-dependent manner. Apoptosis removes the defective, abnormal, or cancerous cells from the body and prevents the development of drug resistance in cancer cells [17]. The ursolic acid-induced apoptosis was also allied with the upregulation of Bax and caspase-3 and 9 and downregulation of BCI-2. In addition to apoptosis, cell cycle arrest is another mechanism responsible for the anticancer activity of several anticancer drugs [13]. Here, we found that ursolic acid halted the division of cells at the G2/M phase of the cell cycle and also reduced the expression of Cyclin B1 and Ccd2 protein expression. Metastasis is an important property of cancer cells [18] and the anti-metastatic potential of SK-MEL-24 cells was investigated by cell migration and invasion assays. We found that ursolic acid inhibited the migration of cancer cells. It is believed that in cancer cells several signal transduction pathways are aberrantly activated and are responsible for the development and progression of cancers. Here, we examined the effects of ursolic acid on the MAPK/ERK signaling pathway and found that ursolic acid blocks this pathway, suggesting the anticancer potential of ursolic acid. However, the evaluation of ursolic acid against more cell lines and under in vivo conditions will provide better insights into the anticancer effects of this molecule.

Conclusions

We found that ursolic acid exhibits considerable anticancer effects on metastatic melanoma cells by activating apoptotic cell death and cell cycle arrest. In addition, ursolic acid also suppresses the migration of melanoma cells, indicating its tremendous potential as an anticancer agent.

Conflict of interest

None.

References:

1. Kinghorn AD, Farnsworth N, Soejarto D et al: Novel strategies for the discovery of plant-derived anticancer agents. Pharmacut Biol, 2003; 41: 53–67
2. Petronelli A, Pannitteri G, Testa U: Triterpenoids as new promising antican cer drugs. Anticancer Drugs, 2009; 20: 880–92
3. Ajayi TO, Moody JO, Fukushi Y et al: Antimicrobial activity of Garcinia kola (Heckel) seed extracts and isolated constituents against caries-causing microorganisms. Afr J Biomed Res, 2014; 17: 165–71
4. Kovacs SD, van Eijk AM, Sevene E et al: The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: A systematic review and meta-analysis. PLoS One, 2016; 11 e0164963
5. Cragg GM, Pezzuto JM: Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princip Practice, 2016; 25: 41–59
6. Kinghorn AD, Farnsworth N, Soejarto D et al: Novel strategies for the discovery of plant-derived anticancer agents. Pharmacut Biol, 2003; 41: 53–67
7. He X, Liu RH: Triterpenoids isolated from apple peels have potent antiproliferative activity and may be partially responsible for apple’s anticancer activity. J Agricult Food Chem, 2007; 55: 4366–70
8. Hsu YL, Kuo PL, Lin CC: Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci, 2004; 75: 2303–16
9. Wu J, Zhao S, Tang Q et al: Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells. J Exp Clin Cancer Res, 2015; 34: 99
10. Robert C, Long GV, Brady B et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 2015; 372(4): 320–30
11. Robert C, Karaszweska B, Schachter J et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 2015; 372(1): 30–39
12. Borowicz S, Van Scoyk M, Avasarala S et al: The soft agar colony formation assay. J Vis Exp, 2014; (92): e51998
13. Li JP, Yang YX, Liu QL et al: The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Design Ther, 2015; 9: 1627
14. Kathagen-Buhmann A, Maire CL, Weller J et al: The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have antiproliferative effects. Neuro Oncol, 2018; 20: 1594–605

15. Van Allen EM, Miao D, Schilling B et al: Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science. 2015; 23: 1–9

16. Prasad S, Yadav VR, Sung B et al: Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. Oncotarget, 2016; 7(11): 13182

17. Mohammad RM, Muqbil I, Lowe L et al: Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol, 2015; 35: 578–103

18. Aceto N, Bardia A, Miyamoto DT et al: Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 2014; 158(5): 1110–22